Lucid Diagnostics Inc. (LUCD)
$0.86
+0.01
(+1.18%)▲
Performance
- $0.83$0.88$0.86
3.49%
Downside
Day's Volatility :5.68%
Upside
2.27%
- $0.63$1.72$0.86
26.73%
Downside
52 Weeks Volatility :63.37%
Upside
50.0%
Returns
| Period | Lucid Diagnostics Inc. | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 24.43% | 6.5% | 0.0% |
6 Months | -40.56% | 7.1% | 0.0% |
1 Year | -37.96% | 9.8% | 0.0% |
3 Years | -92.77% | 14.2% | -20.2% |
Highlights
Market Capitalization | 45.3M |
Book Value | - $0.69 |
Earnings Per Share (EPS) | -1.26 |
Wall Street Target Price | 3.75 |
Profit Margin | 0.0% |
Operating Margin TTM | -1078.12% |
Return On Assets TTM | -69.23% |
Return On Equity TTM | -255.6% |
Revenue TTM | 3.0M |
Revenue Per Share TTM | 0.07 |
Quarterly Revenue Growth YOY | 124.4% |
Gross Profit TTM | -3.2M |
EBITDA | -42.6M |
Diluted Eps TTM | -1.26 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.09 |
EPS Estimate Next Year | -0.73 |
EPS Estimate Current Quarter | -0.27 |
EPS Estimate Next Quarter | -0.25 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 336.05%
Technicals Summary
Sell
Neutral
Buy
Lucid Diagnostics Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Lucid Diagnostics Inc. | 1.09% | -40.56% | -37.96% | -92.77% | -92.77% |
 Stryker Corporation | -3.84% | 5.16% | 12.86% | 24.25% | 52.69% |
 Boston Scientific Corp. | -3.68% | 21.48% | 41.72% | 68.89% | 76.47% |
 Edwards Lifesciences Corp. | -34.8% | -18.49% | -34.85% | -45.17% | -15.86% |
 Abbott Laboratories | 1.03% | -5.4% | -7.12% | -11.35% | 20.75% |
 Medtronic Plc | -1.99% | -9.34% | -13.21% | -38.74% | -23.49% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Lucid Diagnostics Inc. | NA | NA | NA | -1.09 | -2.56 | -0.69 | NA | -0.69 |
Stryker Corporation | 38.91 | 38.91 | 2.92 | 11.95 | 0.19 | 0.07 | 0.01 | 50.33 |
Boston Scientific Corp. | 63.22 | 63.22 | 1.8 | 2.37 | 0.09 | 0.05 | NA | 13.16 |
Edwards Lifesciences Corp. | 36.4 | 36.4 | 5.19 | 2.76 | 0.22 | 0.12 | NA | 12.35 |
Abbott Laboratories | 33.84 | 33.84 | 5.99 | 4.66 | 0.15 | 0.06 | 0.02 | 22.31 |
Medtronic Plc | 28.97 | 28.97 | 1.52 | 5.2 | 0.07 | 0.04 | 0.04 | 38.29 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Lucid Diagnostics Inc. | Buy | $45.3M | -92.77% | NA | 0.0% |
Stryker Corporation | Buy | $129.7B | 52.69% | 38.91 | 16.03% |
Boston Scientific Corp. | Buy | $114.3B | 76.47% | 63.22 | 12.05% |
Edwards Lifesciences Corp. | Buy | $52.4B | -15.86% | 36.4 | 23.74% |
Abbott Laboratories | Buy | $186.6B | 20.75% | 33.84 | 13.65% |
Medtronic Plc | Buy | $102.5B | -23.49% | 28.97 | 11.36% |
Insights on Lucid Diagnostics Inc.
Decreasing Revenue
Revenue is down for the last 2 quarters, 1.04M → 1.00M (in $), with an average decrease of 3.8% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -14.20M → -10.61M (in $), with an average increase of 16.6% per quarter
Vs BSX
In the last 1 year, Boston Scientific Corp. has given 41.7% return, outperforming this stock by 79.7%
Institutional Holdings
Luminus Management, LLC
1.37%Vanguard Group Inc
1.07%Geode Capital Management, LLC
0.30%Nantahala Capital Management, LLC
0.29%HRT FINANCIAL LLC
0.12%BlackRock Inc
0.10%
Company Information
Organization | Lucid Diagnostics Inc. |
Employees | 70 |
CEO | Dr. Lishan Aklog M.D. |
Industry | Healthcare |
